ACE2 and neoplasm: Our results reconcile current knowledge on <i>ACE2</i> expression and suggest that the ISG-type induction of <i>dACE2</i> in IFN-high conditions created by treatments, inflammatory tumor microenvironment, or viral co-infections is unlikely to affect the cellular entry of SARS-CoV-2 and promote infection.